Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 118.21
- Piotroski Score 1.00
- Grade Buy
- Symbol (MLTX)
- Company MoonLake Immunotherapeutics
- Price $47.57
- Changes Percentage (2.52%)
- Change $1.17
- Day Low $45.91
- Day High $48.17
- Year High $64.98
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $76.00
- High Stock Price Target $100.00
- Low Stock Price Target $62.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.72
- Trailing P/E Ratio -57.88
- Forward P/E Ratio -57.88
- P/E Growth -57.88
- Net Income $-36,007,260
Income Statement
Quarterly
Annual
Latest News of MLTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics
Biotechnology Value Fund L.P. reduced its stake in MoonLake Immunotherapeutics by 2,000,000 shares, representing a 9.19% decrease, at $55.28 per share. Despite this reduction, the firm still holds 31....
By Yahoo! Finance | 3 weeks ago -
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the top guru stocks to buy. MLTX is a biotech company developing treatments for psoriasis, focusing on a drug called sonelokimab. With strong cash re...
By Yahoo! Finance | 1 month ago -
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock
The article discusses MoonLake Immunotherapeutics and the challenges faced by foreign companies in the U.S. market. Despite geopolitical tensions, investing in foreign stocks may offer growth opportun...
By Yahoo! Finance | 1 month ago
